Investing

Cathie Wood's ARK Invest Buys Over 7 Million Shares of This Biotech-Focused SPAC

pictures-of-money / Flickr

A couple ARK Invest exchange-traded funds run by ETF star Cathie Wood bought over 7 million shares of Soaring Eagle Acquisition Corp. (NASDAQ: SRNG) on Monday, as the share price of these exchange-traded funds were up around 1% in the day’s session. Their share prices have greatly improved over the past year.

Specifically, ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 4,512,926 shares of the special purpose acquisition company (SPAC), and ARK Innovation ETF (NYSEARCA: ARKK) bought 2,506,461 shares. At Monday’s closing prices, this would have valued this purchase at roughly $70.2 million. This is only a small fraction of the total holdings. ARKG is up 57% over the past 52 weeks and ARKK is up 54%.

Here is a quick look at all the purchases made by ARK ETFs:

Fund Ticker Company Shares
ARKG ADPT Adaptive Biotechnologies 232,610
ARKG SRNG Soaring Eagle Acquisition 4,512,926
ARKG SGFY Signify Health 30,490
ARKK Z Zillow 101,994
ARKK TSP TuSimple 316,814
ARKK SRNG Soaring Eagle Acquisition 2,506,461
ARKQ MKFG Markforged 57,406
ARKQ PATH UiPath 8,178
ARKW LPSN LivePerson 22,696
ARKW Z Zillow 24,750
ARKW PATH UiPath 8,641
ARKX BLDE Blade Air Mobility 16,370
ARKX KTOS Kratos Defense & Security Solutions 49,634


Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.

Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE

Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here
you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.


Click here
to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.